ClinicalTrials.gg
CompletedNCT01162421RADARUpdated Nov 1, 2016Results posted

A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis

A Phase 4 interventional study of adalimumab and Methotrexate in Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2016-11-01.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
60th of 87
77 · median 160
Started
2010
with 3 others
Phase 4
33 of 87
1 open now
Registered
36th of 87
by date
Lead sponsor
7 of 87
AbbVie (prior sponsor, Abbott)

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 60th largest by enrollment, is one of 4 that started in 2010, is one of 33 in phase 4, and was the 36th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

A Canadian study to evaluate early use of adalimumab after methotrexate failure in early rheumatoid arthritis. The study hypothesis will verify if adalimumab effectively reduces joint damage in more participants when introduced earlier than in current practice.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • Anti-Inflammatory
  • Biological Therapy
  • adalimumab
  • Disease-Modifying Antirheumatic Drugs
  • Antirheumatic Agents
  • Agents
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has a diagnosis of Rheumatoid Arthritis as defined by the 1987-revised American College of Rheumatology-classification criteria and has disease duration of less than 2 years from diagnosis.
  2. Subject must have been on a dose of methotrexate therapy either subcutaneously or orally administered (15-25 mg/week) for at least 3 months prior to baseline visit and has had an inadequate response to treatment defined as having a Disease Activity Score DAS28 > 3.2 (at Screening visit).
  3. Subject must also meet the following three criteria (at screening visit): at least 4 swollen joints out of 66 assessed; at least 4 tender joints out of 68 assessed; subject must have an elevated erythrocyte sedimentation rate >/= 20 mm/1h or C-reactive protein > .
  4. Subject must fulfill at least one of the following three criteria: history of rheumatoid factor positive; history of at least one erosion on X-ray or magnetic resonance imaging; history of anti-cyclic-citrullinated protein antibody positive.

Exclusion criteria

Exclusion Criteria:

  1. Subject has previous exposure to any biologic therapy including adalimumab.
  2. Prior disease-modifying antirheumatic drugs triple therapy with methotrexate.
  3. Subject has been treated with intra-articular or parenteral administration of in the preceding 4 weeks prior to baseline visit. Inhaled corticosteroids for stable medical conditions are allowed.
  4. Subject has undergone joint surgery within the preceding two months (at joints to be assessed within the study) of Baseline.
  5. Subject has a poorly controlled medical condition, such as uncontrolled diabetes, unstable heart disease, congestive heart failure, recent cerebrovascular accidents and any other condition which, in the opinion of the Investigator, would put the subject at risk by participating in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Early Adalimumab

    Participants in the Early Adalimumab arm will receive adalimumab and methotrexate at Baseline and every other week for study duration.

    Biological: adalimumab · Drug: Methotrexate

  • Active comparator
    Standard of Care

    Participants in the Standard of Care arm will receive methotrexate and other disease modifying antirheumatic drugs as per local treatment guidelines and study doctor's judgement. Adalimumab may be initiated after a minimum of 6 months.

    Biological: adalimumab · Drug: Methotrexate

Interventions

  • Biologicaladalimumab

    Study drug will be provided to participants in Early Adalimumab arm as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). 40 mg of adalimumab will be administered subcutaneously at Baseline and then every other week for 24 months. Adalimumab may be initiated in participants in standard of care (SOC) arm after a minimum of 6 months of treatment recommended by their study doctor.

    Also known as: ABT-D2E7, Humira

  • Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.

    Also known as: Trexall, Rheumatrex

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With No Radiographic Progression at Month 12

    Radiographic progression was defined as change from Baseline in the modified Total Sharp Score (mTSS) of ≤ 0.5 units). The mTSS is a measure of change in joint health: digitized images of radiographs of hands and feet obtained at Screening and Month 12 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Time frame: Baseline, Month 12

Secondary outcomes

  1. Percentage of Participants With No Radiographic Progression at Month 6 and Month 24

    Radiographic progression was defined as change from Baseline in the modified Total Sharp Score (mTSS) of ≤ 0.5 units). The mTSS is a measure of change in joint health: digitized images of radiographs of hands and feet obtained at Screening and Month 12 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Time frame: Baseline, Month 6, Month 24

  2. Change From Baseline in mTSS at Months 6, 12 and 24

    The mTSS is a measure of change in joint health: digitized images of radiographs of hands and feet obtained at Screening and Month 12 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Time frame: Baseline, Month 6, Month 12, Month 24

  3. Percentage of Participants With Rapid Radiographic Progression at Month 12

    Radiographic progression was defined as a change from Baseline in mTSS that is ≥ 5 units. The mTSS is a measure of change in joint health: digitized images of radiographs of hands and feet obtained at Screening and Month 12 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Time frame: Month 12

  4. Percentage of Participants With American College of Rheumatology 20% (ACR20) Response at Months 3, 6, 9, 12, 18 and 24

    A participant is an ACR20 responder if the following 3 criteria for improvement from Baseline are met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: - * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant (erythrocyte sedimentation rate/C-reactive protein \[CRP\]).

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  5. Percentage of Participants With American College of Rheumatology 50% (ACR50) Response at Months 3, 6, 9, 12, 18 and 24

    A participant is an ACR50 responder if the following 3 criteria for improvement from Baseline are met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant (erythrocyte sedimentation rate/CRP).

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  6. Percentage of Participants With American College of Rheumatology 70% (ACR70) Response at Months 3, 6, 9, 12, 18 and 24

    A participant is an ACR70 responder if the following 3 criteria for improvement from Baseline are met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: - * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant (erythrocyte sedimentation rate/CRP).

    Time frame: Months 3, 6, 9, 12, 18, 24

  7. Change From Baseline in Swollen Joint Count 66 at Months 3, 6, 9, 12, 18 and 24

    Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The presence of swelling is scored 1 and no swelling is 0; range of score is 0-66, with higher scores indicating more swollen joints.

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  8. Change From Baseline in Swollen Joint Count 28 at Months 3, 6, 9, 12, 18 and 24

    Twenty-eight joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The presence of swelling is scored 1 and no swelling is 0; range of score is 0-28, with higher scores indicating more swollen joints.

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  9. Change From Baseline in Tender Joint Count 68 at Months 3, 6, 9, 12, 18 and 24

    Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The presence of tenderness is scored 1 and no tenderness is 0; range of score is 0-68, with higher scores indicating more tender joints.

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  10. Change From Baseline in Tender Joint Count 28 at Months 3, 6, 9, 12, 18 and 24

    Twenty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The presence of tenderness is scored 1 and no tenderness is 0; range of score is 0-28, with higher scores indicating more tender joints.

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  11. Change From Baseline in Physician's Global Assessment of Disease Activity at Months 3, 6, 9, 12, 18 and 24

    Physicians were asked to indicate the participant's disease activity (independent of the participant's self assessment) on a visual analogue scale (VAS) from 0 (very good) to 100 (very bad). A negative change from Baseline indicates improvement.

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  12. Change From Baseline in Patient's Global Assessment of Disease Activity at Months 3, 6, 9, 12, 18 and 24

    Participants were asked to indicate how they were doing with their RA on a VAS from 0 (very well) to 100 (very poorly). A negative change from Baseline indicates improvement.

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  13. Change From Baseline in Patient's Global Assessment of Pain at Months 3, 6, 9, 12, 18 and 24

    Participants were asked to indicate how severe their pain had been in the previous week on a VAS from 0 (no pain) to 100 (pain as bad as it could be). A negative change from Baseline indicates improvement.

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  14. Change From Baseline in CRP at Months 3, 6, 9, 12, 18 and 24

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  15. Change From Baseline in Disease Activity Score DAS28(CRP) at Months 3, 6, 9, 12, 18 and 24

    The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  16. Percentage of Participants With DAS28(CRP) Remission at Months 3, 6, 9, 12, 18 and 24

    DAS28(CRP) remission was defined as DAS28(CRP) \< 2.6. The DAS28(CRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.

    Time frame: Months 3, 6, 9, 12, 18, 24

  17. Percentage of Participants With DAS28(CRP) Low Disease Activity at Months 3, 6, 9, 12, 18 and 24

    DAS28(CRP) low disease activity was defined as DAS28(CRP) \< 3.2. The DAS28(CRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.

    Time frame: Months 3, 6, 9, 12, 18, 24

  18. Percentage of Participants With European League Against Rheumatism (EULAR) Good Response at Months 3, 6, 9, 12, 18 and 24

    A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS28 score. The DAS28 score ranges from 0-10, with higher scores indicating more disease activity. A Good EULAR Response is defined as an improvement (decrease) in the DAS28 of ≥ 1.2 compared with Baseline and attainment of a DAS28 score of ≤ 3.2.

    Time frame: Months 3, 6, 9, 12, 18, 24

  19. Percentage of Participants With EULAR Moderate Response at Months 3, 6, 9, 12, 18 and 24

    A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS28 score. The DAS28 score ranges from 0-10, with higher scores indicating more disease activity. A Moderate EULAR Response is defined as either: an improvement (decrease) in the DAS28 of \> 0.6 and \< 1.2 from Baseline and attainment of a DAS28 score of ≤ 5.1; or an improvement (decrease) in the DAS28 of ≥ 1.2 from Baseline and attainment of a DAS28 score of \> 3.2.

    Time frame: Months 3, 6, 9, 12, 18, 24

  20. Percentage of Participants With Flare-Up After Remission by Month 24

    Percentage of participants with a flare-up after remission by Month 24, defined as participants who reached remission (DAS28 \< 2.6) but later had two consecutive visits with DAS28 ≥ 2.6 (based on observed cases only). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.

    Time frame: Month 24

  21. Change From Baseline in Disability Index of the Health Assessment Questionnaire (HAQ-DI) at Months 3, 6, 9, 12, 18 and 24

    HAQ is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A lower HAQ-DI score is better.

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  22. Percentage of Participants Achieving Minimal Clinical Important Difference (MCID) in HAQ at Months 3, 6, 9, 12, 18 and 24

    The percentage of participants achieving MCID in HAQ, defined as a 0.22 unit decrease in HAQ. HAQ is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A lower HAQ-DI score is better.

    Time frame: Months 3, 6, 9, 12, 18, 24

  23. Percentage of Participants Achieving HAQ < 0.5 at Months 3, 6, 9, 12, 18 and 24

    The percentage of participants achieving HAQ \< 0.5. HAQ is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI \< 0.5. A lower HAQ-DI score is better.

    Time frame: Months 3, 6, 9, 12, 18, 24

  24. Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale at Months 3, 6, 9, 12, 18 and 24

    The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions on a scale from 'not at all' (0) to 'very much' (4). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue.

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  25. Percentage of Participants Achieving MCID in FACIT-Fatigue Scale at Months 3, 6, 9, 12, 18 and 24

    The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions on a scale from 'not at all' (0) to 'very much' (4). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. The MCID was defined as a 3.56-unit decrease in FACIT-Fatigue Scale.

    Time frame: Months 3, 6, 9, 12, 18, 24

  26. Change From Baseline in Work Limitations Questionnaire (WLQ) at Months 3, 6, 9, 12, 18 and 24

    The WLQ was used to measure the impairment in work-related productivity, with reference to the previous two weeks. Each work-related question is scored from 0 to 4 and the total score ranges from 0-100, with lower scores signifying fewer limitations at work.

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  27. Change From Baseline in EuroQOL Questionnaire (EQ-5D) Index Score at Months 3, 6, 9, 12, 18 and 24

    The EQ-5D is a participant answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.594 to 1 (with higher scores indicating better health state).

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  28. Change From Baseline in EQ-5D VAS at Months 3, 6, 9, 12, 18 and 24

    The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.'

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  29. Change From Baseline in Beck Depression Inventory (BDI-II) Scores at Months 3, 6, 9, 12, 18 and 24

    BDI is a 21-item questionnaire, participant self-report rating inventory that measures characteristic attitudes and symptoms of depression. The range of scores is 0 to 63, with a higher value representing a worse outcome.

    Time frame: Baseline, Months 3, 6, 9, 12, 18, 24

  30. Likert Scale for Participant's Satisfaction With Care at Months 3, 6, 9, 12, 18 and 24

    Participants measured their satisfaction with care by specifying their in response to the question "How satisfied are you with the results of your RA treatment?" on a 5-point Likert scale, from the following 5 answers: not satisfied, a little satisfied, moderately satisfied, well satisfied, very well satisfied. Scores range from 1 to 5, with higher scores indicating more satisfaction with their care.

    Time frame: Months 3, 6, 9, 12, 18, 24

  31. Health Care Resources Questionnaire (HCR): Medical Insurance at Baseline

    The HCR consists of four aspects: medical insurance, health care for RA in the past 4 weeks, hospitalization in the past 4 weeks, and out of pocket expenses incurred for the current study condition. Participants were asked whether and what type of health insurance they had. Types of Canadian insurance included: Régie de l'assurance maladie du Québec (RAMQ); Société de l'assurance automobile du Québec (SAAQ); Commission de la santé et de la sécurité du travail (CSST); Canadian Health Insurance Program (CHIP); and L'indemnisation des victimes d'actes criminals (IVAC).

    Time frame: Baseline

  32. HCR: Medical Insurance at Final Visit

    The HCR consists of four aspects: medical insurance, health care for RA in the past 4 weeks, hospitalization in the past 4 weeks, and out of pocket expenses incurred for the current study condition. Participants were asked whether and what type of health insurance they had. Types of Canadian insurance included: Régie de l'assurance maladie du Québec (RAMQ); Société de l'assurance automobile du Québec (SAAQ); Commission de la santé et de la sécurité du travail (CSST); Canadian Health Insurance Program (CHIP); and L'indemnisation des victimes d'actes criminals (IVAC).

    Time frame: Final Visit (up to Month 24)

  33. HCR: Health Care for RA in the Past 4 Weeks at Baseline

    The HCR consists of four aspects: medical insurance, health care for RA in the past 4 weeks, hospitalization in the past 4 weeks, and out of pocket expenses incurred for the current study condition. Participants were asked about their use of health care for RA in the past 4 weeks.

    Time frame: Baseline

  34. HCR: Health Care for RA in the Past 4 Weeks at Final Visit

    The HCR consists of four aspects: medical insurance, health care for RA in the past 4 weeks, hospitalization in the past 4 weeks, and out of pocket expenses incurred for the current study condition. Participants were asked about their use of health care for RA in the past 4 weeks.

    Time frame: Final Visit (up to Month 24)

  35. HCR: Out of Pocket Expenses Incurred for the Current Study Condition in the Past 4 Weeks at Baseline

    The HCR consists of four aspects: medical insurance, health care for RA in the past 4 weeks, hospitalization in the past 4 weeks, and out of pocket expenses incurred for the current study condition. Participants were asked what type of out-of-pocket expenses they had incurred for their RA in the past 4 weeks. Based on Canadian dollars.

    Time frame: Baseline

  36. HCR: Out of Pocket Expenses Incurred for the Current Study Condition in the Past 4 Weeks at Final Visit

    The HCR consists of four aspects: medical insurance, health care for RA in the past 4 weeks, hospitalization in the past 4 weeks, and out of pocket expenses incurred for the current study condition. Participants were asked what type of out-of-pocket expenses they had incurred for their RA in the past 4 weeks. Based on Canadian dollars.

    Time frame: Final Visit (up to Month 24)

07

Results

Posted Nov 1, 2016

Participant flow

Participant flow — Overall Study
MilestoneStandard of CareEarly Adalimumab
Started3740
Completed2927
Not completed813
Withdrew: Did not receive study drug21
Withdrew: Adverse event25
Withdrew: Lost to follow-up02
Withdrew: Lack of efficacy22
Withdrew: Other23

Outcome measures

PrimaryPercentage of Participants With No Radiographic Progression at Month 12

Radiographic progression was defined as change from Baseline in the modified Total Sharp Score (mTSS) of ≤ 0.5 units). The mTSS is a measure of change in joint health: digitized images of radiographs of hands and feet obtained at Screening and Month 12 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

Time frame:
Baseline, Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With No Radiographic Progression at Month 12
percentage of participantsStandard of CareEarly Adalimumab
Percentage of Participants With No Radiographic Progression at Month 1262.961.5
Statistical analysis
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.907 · Difference in percentage: -1.3 · 95% CI -23.4 to 20.8P-value is based on two-sided Pearson's chi-square test.
SecondaryPercentage of Participants With No Radiographic Progression at Month 6 and Month 24

Radiographic progression was defined as change from Baseline in the modified Total Sharp Score (mTSS) of ≤ 0.5 units). The mTSS is a measure of change in joint health: digitized images of radiographs of hands and feet obtained at Screening and Month 12 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

Time frame:
Baseline, Month 6, Month 24
Reported as:
Number · percentage of participants
Percentage of Participants With No Radiographic Progression at Month 6 and Month 24
percentage of participantsStandard of CareEarly Adalimumab
Month 668.671.8
Month 2451.446.2
Statistical analysis
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.762 · Difference in percentage: 3.2 · 95% CI -17.7 to 24.1P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.650 · Difference in percentage: -5.3 · 95% CI -28.1 to 17.5P-value is based on two-sided Pearson's chi-square test.
SecondaryChange From Baseline in mTSS at Months 6, 12 and 24

The mTSS is a measure of change in joint health: digitized images of radiographs of hands and feet obtained at Screening and Month 12 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

Time frame:
Baseline, Month 6, Month 12, Month 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in mTSS at Months 6, 12 and 24
units on a scaleStandard of CareEarly Adalimumab
Month 6; n=34, 360.88 ± 0.2730.02 ± 0.266
Month 12; n=30, 341.62 ± 0.4860.16 ± 0.457
Month 24; n=28, 212.24 ± 0.9120.01 ± 1.055
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.027 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and baseline value as the covariate.) · Least squares (ls) mean difference: -0.86 · 95% CI -1.62 to -0.10The a priori threshold for statistical significance is P= 0.05.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.033 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and baseline value as the covariate.) · Ls mean difference: -1.46 · 95% CI -2.79 to -0.12The a priori threshold for statistical significance is P= 0.05.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.120 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and baseline value as the covariate.) · Ls mean difference: -2.22 · 95% CI -5.05 to 0.60
SecondaryPercentage of Participants With Rapid Radiographic Progression at Month 12

Radiographic progression was defined as a change from Baseline in mTSS that is ≥ 5 units. The mTSS is a measure of change in joint health: digitized images of radiographs of hands and feet obtained at Screening and Month 12 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Rapid Radiographic Progression at Month 12
percentage of participantsStandard of CareEarly Adalimumab
Percentage of Participants With Rapid Radiographic Progression at Month 1214.32.6
Statistical analysis
  • Standard of Care vs Early Adalimumab · Fisher Exact · p = 0.095 (P-value is based on two sided Fisher's exact test.) · Difference in percentage: -11.7 · 95% CI -27.0 to 1.6Confidence interval is based on Wilson confidence limits.
SecondaryPercentage of Participants With American College of Rheumatology 20% (ACR20) Response at Months 3, 6, 9, 12, 18 and 24

A participant is an ACR20 responder if the following 3 criteria for improvement from Baseline are met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: - * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant (erythrocyte sedimentation rate/C-reactive protein \[CRP\]).

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology 20% (ACR20) Response at Months 3, 6, 9, 12, 18 and 24
percentage of participantsStandard of CareEarly Adalimumab
Month 357.169.2
Month 637.164.1
Month 960.066.7
Month 1268.656.4
Month 1865.751.3
Month 2465.746.2
Statistical analysis
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.281 · Difference in percentage: 12.1 · 95% CI -9.79 to 33.97P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.021 (The a priori threshold for statistical significance is P=0.05.) · Difference in percentage: 27.0 · 95% CI 4.98 to 48.93P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.552 · Difference in percentage: 6.7 · 95% CI -15.29 to 28.63P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.281 · Difference in percentage: -12.2 · 95% CI -34.04 to 9.72P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.209 · Difference in percentage: -14.4 · 95% CI -36.64 to 7.78P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.091 · Difference in percentage: -19.6 · 95% CI -41.74 to 2.62P-value is based on two-sided Pearson's chi-square test.
SecondaryPercentage of Participants With American College of Rheumatology 50% (ACR50) Response at Months 3, 6, 9, 12, 18 and 24

A participant is an ACR50 responder if the following 3 criteria for improvement from Baseline are met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant (erythrocyte sedimentation rate/CRP).

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology 50% (ACR50) Response at Months 3, 6, 9, 12, 18 and 24
percentage of participantsStandard of CareEarly Adalimumab
Month 322.938.5
Month 622.943.6
Month 940.048.7
Month 1234.343.6
Month 1845.738.5
Month 2442.933.3
Statistical analysis
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.148 · Difference in percentage: 15.6 · 95% CI -5.05 to 36.26P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.060 · Difference in percentage: 20.7 · 95% CI -0.14 to 41.61P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.451 · Difference in percentage: 8.7 · 95% CI -13.85 to 31.29P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.413 · Difference in percentage: 9.3 · 95% CI -12.82 to 31.43P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.528 · Difference in percentage: -7.3 · 95% CI -29.74 to 15.23P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.399 · Difference in percentage: -9.5 · 95% CI -31.61 to 12.56P-value is based on two-sided Pearson's chi-square test.
SecondaryPercentage of Participants With American College of Rheumatology 70% (ACR70) Response at Months 3, 6, 9, 12, 18 and 24

A participant is an ACR70 responder if the following 3 criteria for improvement from Baseline are met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: - * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant (erythrocyte sedimentation rate/CRP).

Time frame:
Months 3, 6, 9, 12, 18, 24
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology 70% (ACR70) Response at Months 3, 6, 9, 12, 18 and 24
percentage of participantsStandard of CareEarly Adalimumab
Month 32.915.4
Month 68.628.2
Month 922.925.6
Month 1214.330.8
Month 1820.030.8
Month 2440.023.1
Statistical analysis
  • Standard of Care vs Early Adalimumab · Fisher Exact · p = 0.111 · Difference in percentage: 12.5 · 95% CI -1.70 to 27.06
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.031 (The a priori threshold for statistical significance is P=0.05.) · Difference in percentage: 19.6 · 95% CI 2.74 to 36.53P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.780 · Difference in percentage: 2.8 · 95% CI -16.74 to 22.31P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.092 · Difference in percentage: 16.5 · 95% CI -2.07 to 35.04P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.290 · Difference in percentage: 10.8 · 95% CI -8.86 to 30.40P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.116 · Difference in percentage: -16.9 · 95% CI -37.86 to 4.01P-value is based on two-sided Pearson's chi-square test.
SecondaryChange From Baseline in Swollen Joint Count 66 at Months 3, 6, 9, 12, 18 and 24

Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The presence of swelling is scored 1 and no swelling is 0; range of score is 0-66, with higher scores indicating more swollen joints.

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · swollen joints
Change From Baseline in Swollen Joint Count 66 at Months 3, 6, 9, 12, 18 and 24
swollen jointsStandard of CareEarly Adalimumab
Month 3-5.6 ± 0.85-9.2 ± 0.81
Month 6-5.9 ± 0.81-10.4 ± 0.78
Month 9-8.1 ± 0.84-10.8 ± 0.80
Month 12-9.2 ± 0.69-11.3 ± 0.66
Month 18-9.4 ± 1.14-10.0 ± 1.09
Month 24-10.1 ± 0.83-10.6 ± 0.80
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.004 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -3.5 · 95% CI -5.9 to -1.2The a priori threshold for statistical significance is P=0.01.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = <0.001 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -4.5 · 95% CI -6.8 to -2.3The a priori threshold for statistical significance is P=0.001.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.021 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -2.7 · 95% CI -5.1 to -0.4The a priori threshold for statistical significance is P=0.05.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.037 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -2.0 · 95% CI -4.0 to -0.1The a priori threshold for statistical significance is P=0.05.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.702 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.6 · 95% CI -3.7 to 2.5
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.644 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.5 · 95% CI -2.8 to 1.8
SecondaryChange From Baseline in Swollen Joint Count 28 at Months 3, 6, 9, 12, 18 and 24

Twenty-eight joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The presence of swelling is scored 1 and no swelling is 0; range of score is 0-28, with higher scores indicating more swollen joints.

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · swollen joints
Change From Baseline in Swollen Joint Count 28 at Months 3, 6, 9, 12, 18 and 24
swollen jointsStandard of CareEarly Adalimumab
Month 3-4.6 ± 0.64-6.5 ± 0.62
Month 6-4.5 ± 0.57-7.9 ± 0.55
Month 9-6.1 ± 0.58-8.3 ± 0.56
Month 12-6.9 ± 0.51-8.5 ± 0.49
Month 18-7.4 ± 0.68-8.1 ± 0.65
Month 24-7.6 ± 0.55-8.4 ± 0.53
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.039 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -1.9 · 95% CI -3.7 to -0.1The a priori threshold for statistical significance is P=0.05.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = <0.001 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -3.4 · 95% CI -5.0 to -1.8The a priori threshold for statistical significance is P=0.001.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.008 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -2.2 · 95% CI -3.8 to -0.6The a priori threshold for statistical significance is P=0.01.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.028 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -1.6 · 95% CI -3.0 to -0.2The a priori threshold for statistical significance is P=0.05.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.452 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.7 · 95% CI -2.6 to 1.2
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.343 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.7 · 95% CI -2.3 to 0.8
SecondaryChange From Baseline in Tender Joint Count 68 at Months 3, 6, 9, 12, 18 and 24

Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The presence of tenderness is scored 1 and no tenderness is 0; range of score is 0-68, with higher scores indicating more tender joints.

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · tender joints
Change From Baseline in Tender Joint Count 68 at Months 3, 6, 9, 12, 18 and 24
tender jointsStandard of CareEarly Adalimumab
Month 3-9.3 ± 1.63-12.1 ± 1.56
Month 6-8.3 ± 1.38-15.5 ± 1.33
Month 9-11.2 ± 1.35-15.0 ± 1.30
Month 12-13.4 ± 1.41-14.1 ± 1.35
Month 18-13.4 ± 1.67-13.9 ± 1.60
Month 24-15.0 ± 1.32-15.8 ± 1.27
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.220 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -2.8 · 95% CI -7.3 to 1.7
  • Standard of Care vs Early Adalimumab · ANCOVA · p = <0.001 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -7.2 · 95% CI -11.0 to -3.3The a priori threshold for statistical significance is P=0.001.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.050 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -3.7 · 95% CI -7.5 to 0.0The a priori threshold for statistical significance is P=0.05.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.725 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.7 · 95% CI -4.6 to 3.2
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.837 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.5 · 95% CI -5.1 to 4.1
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.661 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.8 · 95% CI -4.5 to 2.9
SecondaryChange From Baseline in Tender Joint Count 28 at Months 3, 6, 9, 12, 18 and 24

Twenty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The presence of tenderness is scored 1 and no tenderness is 0; range of score is 0-28, with higher scores indicating more tender joints.

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · tender joints
Change From Baseline in Tender Joint Count 28 at Months 3, 6, 9, 12, 18 and 24
tender jointsStandard of CareEarly Adalimumab
Month 3-5.5 ± 0.93-7.4 ± 0.90
Month 6-5.7 ± 0.78-9.7 ± 0.74
Month 9-7.1 ± 0.86-9.6 ± 0.83
Month 12-8.4 ± 0.82-9.2 ± 0.79
Month 18-8.5 ± 0.94-9.1 ± 0.90
Month 24-9.4 ± 0.80-10.2 ± 0.77
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.156 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -1.9 · 95% CI -4.4 to 0.7
  • Standard of Care vs Early Adalimumab · ANCOVA · p = <0.001 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -4.0 · 95% CI -6.1 to -1.9The a priori threshold for statistical significance is P=0.001.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.040 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -2.5 · 95% CI -4.9 to -0.1The a priori threshold for statistical significance is P=0.05.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.492 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.8 · 95% CI -3.1 to 1.5
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.649 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.6 · 95% CI -3.2 to 2.0
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.464 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.8 · 95% CI -3.0 to 1.4
SecondaryChange From Baseline in Physician's Global Assessment of Disease Activity at Months 3, 6, 9, 12, 18 and 24

Physicians were asked to indicate the participant's disease activity (independent of the participant's self assessment) on a visual analogue scale (VAS) from 0 (very good) to 100 (very bad). A negative change from Baseline indicates improvement.

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Physician's Global Assessment of Disease Activity at Months 3, 6, 9, 12, 18 and 24
units on a scaleStandard of CareEarly Adalimumab
Month 3-29.3 ± 3.66-41.6 ± 3.51
Month 6-22.5 ± 4.25-48.0 ± 4.08
Month 9-39.6 ± 4.21-48.9 ± 4.04
Month 12-43.8 ± 4.12-47.3 ± 3.96
Month 18-45.5 ± 4.29-46.2 ± 4.12
Month 24-47.6 ± 4.23-47.7 ± 4.06
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.018 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -12.3 · 95% CI -22.5 to -2.2The a priori threshold for statistical significance is P=0.05.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = <0.001 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -25.5 · 95% CI -37.3 to -13.7The a priori threshold for statistical significance is P=0.001.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.113 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -9.4 · 95% CI -21.0 to 2.3
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.544 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -3.5 · 95% CI -14.9 to 7.9
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.916 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.6 · 95% CI -12.5 to 11.2
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.983 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.1 · 95% CI -11.8 to 11.6
SecondaryChange From Baseline in Patient's Global Assessment of Disease Activity at Months 3, 6, 9, 12, 18 and 24

Participants were asked to indicate how they were doing with their RA on a VAS from 0 (very well) to 100 (very poorly). A negative change from Baseline indicates improvement.

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Patient's Global Assessment of Disease Activity at Months 3, 6, 9, 12, 18 and 24
units on a scaleStandard of CareEarly Adalimumab
Month 3-19.5 ± 3.58-21.8 ± 3.43
Month 6-14.4 ± 4.05-19.6 ± 3.88
Month 9-25.4 ± 4.02-20.2 ± 3.86
Month 12-22.4 ± 3.81-22.3 ± 3.65
Month 18-29.4 ± 3.86-23.0 ± 3.71
Month 24-30.6 ± 3.99-23.6 ± 3.83
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.641 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -2.3 · 95% CI -12.2 to 7.6
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.358 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -5.2 · 95% CI -16.4 to 6.0
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.352 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 5.2 · 95% CI -5.9 to 16.4
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.990 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.1 · 95% CI -10.5 to 10.6
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.238 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 6.4 · 95% CI -4.3 to 17.1
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.207 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 7.1 · 95% CI -4.0 to 18.1
SecondaryChange From Baseline in Patient's Global Assessment of Pain at Months 3, 6, 9, 12, 18 and 24

Participants were asked to indicate how severe their pain had been in the previous week on a VAS from 0 (no pain) to 100 (pain as bad as it could be). A negative change from Baseline indicates improvement.

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Patient's Global Assessment of Pain at Months 3, 6, 9, 12, 18 and 24
units on a scaleStandard of CareEarly Adalimumab
Month 3-22.0 ± 3.79-23.0 ± 3.64
Month 6-14.5 ± 3.94-23.0 ± 3.78
Month 9-21.7 ± 4.03-21.3 ± 3.87
Month 12-22.0 ± 4.01-24.4 ± 3.85
Month 18-28.1 ± 4.07-22.7 ± 3.90
Month 24-26.6 ± 4.40-23.6 ± 4.22
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.850 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -1.0 · 95% CI -11.5 to 9.5
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.129 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -8.4 · 95% CI -19.4 to 2.5
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.937 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.4 · 95% CI -10.8 to 11.6
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.670 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -2.4 · 95% CI -13.5 to 8.8
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.341 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 5.4 · 95% CI -5.9 to 16.7
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.621 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 3.0 · 95% CI -9.2 to 15.3
SecondaryChange From Baseline in CRP at Months 3, 6, 9, 12, 18 and 24
Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · mg/L
Change From Baseline in CRP at Months 3, 6, 9, 12, 18 and 24
mg/LStandard of CareEarly Adalimumab
Month 3; n=33, 38-10.2 ± 2.39-8.9 ± 2.23
Month 6; n=34, 38-7.6 ± 3.26-9.1 ± 3.08
Month 9; n=35, 38-11.3 ± 2.84-11.1 ± 2.72
Month 12; n=35, 38-13.7 ± 2.37-10.8 ± 2.28
Month 18; n=35, 38-15.2 ± 2.51-9.7 ± 2.41
Month 24; n=26, 23-13.5 ± 2.46-11.2 ± 2.36
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.697 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 1.3 · 95% CI -5.3 to 7.9
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.744 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -1.5 · 95% CI -10.5 to 7.5
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.967 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.2 · 95% CI -7.7 to 8.0
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.377 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 2.9 · 95% CI -3.7 to 9.5
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.122 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 5.5 · 95% CI -1.5 to 12.4
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.490 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 2.4 · 95% CI -4.4 to 9.2
SecondaryChange From Baseline in Disease Activity Score DAS28(CRP) at Months 3, 6, 9, 12, 18 and 24

The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Disease Activity Score DAS28(CRP) at Months 3, 6, 9, 12, 18 and 24
units on a scaleStandard of CareEarly Adalimumab
Month 3; n=33, 38-1.4 ± 0.20-1.8 ± 0.18
Month 6; n=34, 38-1.4 ± 0.21-2.3 ± 0.20
Month 9; n=35, 38-2.0 ± 0.21-2.3 ± 0.20
Month 12; n=35, 38-2.1 ± 0.20-2.4 ± 0.19
Month 18; n=35, 38-2.4 ± 0.22-2.4 ± 0.21
Month 24; n=35, 38-2.6 ± 0.20-2.6 ± 0.19
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.102 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.4 · 95% CI -1.0 to 0.1
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.003 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.9 · 95% CI -1.5 to -0.3The a priori threshold for statistical significance is P=0.01.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.214 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.4 · 95% CI -0.9 to 0.2
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.339 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.3 · 95% CI -0.8 to 0.3
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.973 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: 0.0 · 95% CI -0.6 to 0.6
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.755 (P-values are two-sided and are based on repeated measures ANCOVA model with treatment group and visit as the fixed effects and Baseline value as the covariate.) · Ls mean difference: -0.1 · 95% CI -0.6 to 0.5
SecondaryPercentage of Participants With DAS28(CRP) Remission at Months 3, 6, 9, 12, 18 and 24

DAS28(CRP) remission was defined as DAS28(CRP) \< 2.6. The DAS28(CRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.

Time frame:
Months 3, 6, 9, 12, 18, 24
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28(CRP) Remission at Months 3, 6, 9, 12, 18 and 24
percentage of participantsStandard of CareEarly Adalimumab
Month 38.617.9
Month 611.435.9
Month 931.428.2
Month 1222.935.9
Month 1834.330.8
Month 2442.938.5
Statistical analysis
  • Standard of Care vs Early Adalimumab · Fisher Exact · p = 0.316 · Difference in percentage: 9.4 · 95% CI -7.09 to 25.13Two-sided Fisher Exact test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.014 · Difference in percentage: 24.5 · 95% CI 6.09 to 42.85P-value is based on two-sided Pearson's chi-square test. The a priori threshold for statistical significance is P=0.05.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.762 · Difference in percentage: -3.2 · 95% CI -24.10 to 17.66P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.220 · Difference in percentage: 13.0 · 95% CI -7.46 to 33.54P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.747 · Difference in percentage: -3.5 · 95% CI -24.90 to 17.86P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.701 · Difference in percentage: -4.4 · 95% CI -26.80 to 18.01P-value is based on two-sided Pearson's chi-square test.
SecondaryPercentage of Participants With DAS28(CRP) Low Disease Activity at Months 3, 6, 9, 12, 18 and 24

DAS28(CRP) low disease activity was defined as DAS28(CRP) \< 3.2. The DAS28(CRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.

Time frame:
Months 3, 6, 9, 12, 18, 24
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28(CRP) Low Disease Activity at Months 3, 6, 9, 12, 18 and 24
percentage of participantsStandard of CareEarly Adalimumab
Month 322.933.3
Month 628.651.3
Month 951.456.4
Month 1248.656.4
Month 1851.448.7
Month 2454.343.6
Statistical analysis
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.318 · Difference in percentage: 10.5 · 95% CI -9.83 to 30.78P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.047 · Difference in percentage: 22.7 · 95% CI 1.03 to 44.39P-value is based on two-sided Pearson's chi-square test. The a priori threshold for statistical significance is P=0.05.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.668 · Difference in percentage: 5.0 · 95% CI -17.74 to 27.71P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.500 · Difference in percentage: 7.8 · 95% CI -14.88 to 30.56P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.816 · Difference in percentage: -2.7 · 95% CI -25.52 to 20.10P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.358 · Difference in percentage: -10.7 · 95% CI -33.38 to 11.99P-value is based on two-sided Pearson's chi-square test.
SecondaryPercentage of Participants With European League Against Rheumatism (EULAR) Good Response at Months 3, 6, 9, 12, 18 and 24

A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS28 score. The DAS28 score ranges from 0-10, with higher scores indicating more disease activity. A Good EULAR Response is defined as an improvement (decrease) in the DAS28 of ≥ 1.2 compared with Baseline and attainment of a DAS28 score of ≤ 3.2.

Time frame:
Months 3, 6, 9, 12, 18, 24
Reported as:
Number · percentage of participants
Percentage of Participants With European League Against Rheumatism (EULAR) Good Response at Months 3, 6, 9, 12, 18 and 24
percentage of participantsStandard of CareEarly Adalimumab
Month 322.930.8
Month 628.648.7
Month 948.651.3
Month 1245.753.8
Month 1851.448.7
Month 2454.343.6
Statistical analysis
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.444 · Difference in percentage: 7.9 · 95% CI -12.17 to 28.00P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.076 · Difference in percentage: 20.1 · 95% CI -1.53 to 41.83P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.816 · Difference in percentage: 2.7 · 95% CI -20.10 to 25.52P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.485 · Difference in percentage: 8.1 · 95% CI -14.61 to 30.87P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.816 · Difference in percentage: -2.7 · 95% CI -25.52 to 20.10P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.358 · Difference in percentage: -10.7 · 95% CI -33.38 to 11.99P-value is based on two-sided Pearson's chi-square test.
SecondaryPercentage of Participants With EULAR Moderate Response at Months 3, 6, 9, 12, 18 and 24

A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS28 score. The DAS28 score ranges from 0-10, with higher scores indicating more disease activity. A Moderate EULAR Response is defined as either: an improvement (decrease) in the DAS28 of \> 0.6 and \< 1.2 from Baseline and attainment of a DAS28 score of ≤ 5.1; or an improvement (decrease) in the DAS28 of ≥ 1.2 from Baseline and attainment of a DAS28 score of \> 3.2.

Time frame:
Months 3, 6, 9, 12, 18, 24
Reported as:
Number · percentage of participants
Percentage of Participants With EULAR Moderate Response at Months 3, 6, 9, 12, 18 and 24
percentage of participantsStandard of CareEarly Adalimumab
Month 337.148.7
Month 625.730.8
Month 928.628.2
Month 1237.123.1
Month 1822.910.3
Month 2414.310.3
Statistical analysis
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.316 · Difference in percentage: 11.6 · 95% CI -10.84 to 33.99P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.630 · Difference in percentage: 5.1 · 95% CI -15.43 to 25.54P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.972 · Difference in percentage: -0.4 · 95% CI -20.94 to 20.21P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.186 · Difference in percentage: -14.1 · 95% CI -34.83 to 6.70P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.142 · Difference in percentage: -12.6 · 95% CI -29.46 to 4.26P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.727 · Difference in percentage: -4.0 · 95% CI -20.34 to 11.52P-value is based on two-sided Pearson's chi-square test.
SecondaryPercentage of Participants With Flare-Up After Remission by Month 24

Percentage of participants with a flare-up after remission by Month 24, defined as participants who reached remission (DAS28 \< 2.6) but later had two consecutive visits with DAS28 ≥ 2.6 (based on observed cases only). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.

Time frame:
Month 24
Reported as:
Number · percentage of participants
Percentage of Participants With Flare-Up After Remission by Month 24
percentage of participantsStandard of CareEarly Adalimumab
Percentage of Participants With Flare-Up After Remission by Month 248.615.4
Statistical analysis
  • Standard of Care vs Early Adalimumab · Fisher Exact · p = 0.486 · Difference in percentage: 6.8 · 95% CI -9.21 to 22.22Two-sided Fisher Exact test.
SecondaryChange From Baseline in Disability Index of the Health Assessment Questionnaire (HAQ-DI) at Months 3, 6, 9, 12, 18 and 24

HAQ is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A lower HAQ-DI score is better.

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Disability Index of the Health Assessment Questionnaire (HAQ-DI) at Months 3, 6, 9, 12, 18 and 24
units on a scaleStandard of CareEarly Adalimumab
Month 3-0.41 ± 0.094-0.38 ± 0.090
Month 6-0.29 ± 0.095-0.46 ± 0.092
Month 9-0.52 ± 0.095-0.50 ± 0.092
Month 12-0.60 ± 0.093-0.50 ± 0.089
Month 18-0.60 ± 0.102-0.55 ± 0.098
Month 24-0.61 ± 0.107-0.53 ± 0.102
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.809 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.03 · 95% CI -0.23 to 0.29
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.194 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -0.17 · 95% CI -0.44 to 0.09
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.863 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.02 · 95% CI -0.24 to 0.29
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.452 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.10 · 95% CI -0.16 to 0.35
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.738 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.05 · 95% CI -0.23 to 0.33
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.572 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.08 · 95% CI -0.21 to 0.38
SecondaryPercentage of Participants Achieving Minimal Clinical Important Difference (MCID) in HAQ at Months 3, 6, 9, 12, 18 and 24

The percentage of participants achieving MCID in HAQ, defined as a 0.22 unit decrease in HAQ. HAQ is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A lower HAQ-DI score is better.

Time frame:
Months 3, 6, 9, 12, 18, 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Minimal Clinical Important Difference (MCID) in HAQ at Months 3, 6, 9, 12, 18 and 24
percentage of participantsStandard of CareEarly Adalimumab
Month 365.753.8
Month 654.351.3
Month 957.164.1
Month 1268.659.0
Month 1857.153.8
Month 2457.141.0
Statistical analysis
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.299 · Difference in percentage: -11.9 · 95% CI -34.05 to 10.31P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.796 · Difference in percentage: -3.0 · 95% CI -25.77 to 19.77P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.540 · Difference in percentage: 7.0 · 95% CI -15.30 to 29.22P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.392 · Difference in percentage: -9.6 · 95% CI -31.39 to 12.19P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.776 · Difference in percentage: -3.3 · 95% CI -25.96 to 19.37P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.166 · Difference in percentage: -16.1 · 95% CI -38.64 to 6.40P-value is based on two-sided Pearson's chi-square test.
SecondaryPercentage of Participants Achieving HAQ < 0.5 at Months 3, 6, 9, 12, 18 and 24

The percentage of participants achieving HAQ \< 0.5. HAQ is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI \< 0.5. A lower HAQ-DI score is better.

Time frame:
Months 3, 6, 9, 12, 18, 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HAQ < 0.5 at Months 3, 6, 9, 12, 18 and 24
percentage of participantsStandard of CareEarly Adalimumab
Month 331.420.5
Month 622.930.8
Month 934.335.9
Month 1234.333.3
Month 1828.630.8
Month 2428.630.8
Statistical analysis
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.283 · Difference in percentage: -10.9 · 95% CI -30.84 to 9.01P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.444 · Difference in percentage: 7.9 · 95% CI -12.17 to 28.00P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.885 · Difference in percentage: 1.6 · 95% CI -20.16 to 23.38P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.931 · Difference in percentage: -1.0 · 95% CI -22.54 to 20.64P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.836 · Difference in percentage: 2.2 · 95% CI -18.63 to 23.03P-value is based on two-sided Pearson's chi-square test.
  • Standard of Care vs Early Adalimumab · Chi-squared · p = 0.836 · Difference in percentage: 2.2 · 95% CI -18.63 to 23.03P-value is based on two-sided Pearson's chi-square test.
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale at Months 3, 6, 9, 12, 18 and 24

The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions on a scale from 'not at all' (0) to 'very much' (4). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue.

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale at Months 3, 6, 9, 12, 18 and 24
units on a scaleStandard of CareEarly Adalimumab
Month 37.1 ± 1.628.0 ± 1.56
Month 65.4 ± 1.778.2 ± 1.70
Month 99.5 ± 1.708.0 ± 1.63
Month 1210.7 ± 1.808.0 ± 1.73
Month 1810.2 ± 1.988.2 ± 1.90
Month 249.8 ± 2.008.8 ± 1.92
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.699 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.9 · 95% CI -3.6 to 5.4
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.261 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 2.8 · 95% CI -2.1 to 7.7
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.514 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -1.5 · 95% CI -6.2 to 3.2
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.283 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -2.7 · 95% CI -7.7 to 2.3
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.461 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -2.0 · 95% CI -7.5 to 3.4
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.703 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -1.1 · 95% CI -6.6 to 4.5
SecondaryPercentage of Participants Achieving MCID in FACIT-Fatigue Scale at Months 3, 6, 9, 12, 18 and 24

The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions on a scale from 'not at all' (0) to 'very much' (4). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. The MCID was defined as a 3.56-unit decrease in FACIT-Fatigue Scale.

Time frame:
Months 3, 6, 9, 12, 18, 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving MCID in FACIT-Fatigue Scale at Months 3, 6, 9, 12, 18 and 24
percentage of participantsStandard of CareEarly Adalimumab
Month 314.313.2
Month 614.37.9
Month 917.15.3
Month 128.613.2
Month 188.615.8
Month 2411.45.3
Statistical analysis
  • Standard of Care vs Early Adalimumab · Fisher Exact · p = 1.000 · Difference in percentage: -1.1 · 95% CI -17.94 to 15.16Two-sided Fisher Exact test.
  • Standard of Care vs Early Adalimumab · Fisher Exact · p = 0.468 · Difference in percentage: -6.4 · 95% CI -22.34 to 8.81Two-sided Fisher Exact test.
  • Standard of Care vs Early Adalimumab · Fisher Exact · p = 0.142 · Difference in percentage: -11.9 · 95% CI -27.88 to 3.16Two-sided Fisher Exact test.
  • Standard of Care vs Early Adalimumab · Fisher Exact · p = 0.712 · Difference in percentage: 4.6 · 95% CI -11.08 to 19.83Two-sided Fisher Exact test.
  • Standard of Care vs Early Adalimumab · Fisher Exact · p = 0.482 · Difference in percentage: 7.2 · 95% CI -8.92 to 22.89Two-sided Fisher Exact test.
  • Standard of Care vs Early Adalimumab · Fisher Exact · p = 0.418 · Difference in percentage: -6.2 · 95% CI -21.18 to 7.69Two-sided Fisher Exact test.
SecondaryChange From Baseline in Work Limitations Questionnaire (WLQ) at Months 3, 6, 9, 12, 18 and 24

The WLQ was used to measure the impairment in work-related productivity, with reference to the previous two weeks. Each work-related question is scored from 0 to 4 and the total score ranges from 0-100, with lower scores signifying fewer limitations at work.

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Work Limitations Questionnaire (WLQ) at Months 3, 6, 9, 12, 18 and 24
units on a scaleStandard of CareEarly Adalimumab
Month 3; n=23, 24-7.0 ± 4.18-11.5 ± 4.10
Month 6; n=24, 25-6.1 ± 4.20-13.9 ± 4.11
Month 9; n=25, 25-8.4 ± 4.45-11.8 ± 4.45
Month 12; n=25, 25-15.2 ± 4.05-11.8 ± 4.05
Month 18; n=25, 25-15.6 ± 4.51-12.8 ± 4.51
Month 24; n=25, 25-13.7 ± 4.34-12.6 ± 4.34
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.453 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -4.4 · 95% CI -16.3 to 7.4
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.187 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -7.9 · 95% CI -19.7 to 4.0
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.598 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -3.4 · 95% CI -16.1 to 9.4
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.558 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 3.4 · 95% CI -8.2 to 15.0
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.669 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 2.7 · 95% CI -10.1 to 15.6
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.865 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 1.1 · 95% CI -11.3 to 13.5
SecondaryChange From Baseline in EuroQOL Questionnaire (EQ-5D) Index Score at Months 3, 6, 9, 12, 18 and 24

The EQ-5D is a participant answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.594 to 1 (with higher scores indicating better health state).

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in EuroQOL Questionnaire (EQ-5D) Index Score at Months 3, 6, 9, 12, 18 and 24
units on a scaleStandard of CareEarly Adalimumab
Month 3; n=34, 340.21 ± 0.0410.22 ± 0.041
Month 6; n=35, 360.18 ± 0.0440.23 ± 0.044
Month 9; n=35, 360.26 ± 0.0440.22 ± 0.044
Month 12; n=35, 360.25 ± 0.0400.26 ± 0.040
Month 18; n=35, 360.25 ± 0.0450.24 ± 0.045
Month 24; n=35, 360.26 ± 0.0490.22 ± 0.049
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.809 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.01 · 95% CI -0.10 to 0.13
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.447 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.05 · 95% CI -0.08 to 0.17
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.579 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -0.03 · 95% CI -0.16 to 0.09
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.922 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.01 · 95% CI -0.11 to 0.12
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.894 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -0.01 · 95% CI -0.14 to 0.12
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.611 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -0.04 · 95% CI -0.17 to 0.10
SecondaryChange From Baseline in EQ-5D VAS at Months 3, 6, 9, 12, 18 and 24

The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.'

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in EQ-5D VAS at Months 3, 6, 9, 12, 18 and 24
units on a scaleStandard of CareEarly Adalimumab
Month 318.7 ± 3.1816.2 ± 3.05
Month 610.7 ± 3.7018.6 ± 3.55
Month 920.1 ± 3.7817.7 ± 3.63
Month 1222.2 ± 3.4619.5 ± 3.32
Month 1822.3 ± 3.6221.2 ± 3.47
Month 2422.1 ± 4.1119.7 ± 3.95
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.572 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -2.5 · 95% CI -11.3 to 6.3
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.130 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 7.9 · 95% CI -2.4 to 18.2
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.649 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -2.4 · 95% CI -12.9 to 8.1
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.579 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -2.7 · 95% CI -12.3 to 6.9
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.826 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -1.1 · 95% CI -11.1 to 8.9
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.675 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -2.4 · 95% CI -13.8 to 9.0
SecondaryChange From Baseline in Beck Depression Inventory (BDI-II) Scores at Months 3, 6, 9, 12, 18 and 24

BDI is a 21-item questionnaire, participant self-report rating inventory that measures characteristic attitudes and symptoms of depression. The range of scores is 0 to 63, with a higher value representing a worse outcome.

Time frame:
Baseline, Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Beck Depression Inventory (BDI-II) Scores at Months 3, 6, 9, 12, 18 and 24
units on a scaleStandard of CareEarly Adalimumab
Month 3-4.3 ± 1.15-3.1 ± 1.07
Month 6-1.0 ± 1.28-2.4 ± 1.19
Month 9-4.3 ± 1.04-3.7 ± 0.97
Month 12-5.1 ± 1.24-3.5 ± 1.15
Month 18-4.8 ± 1.22-3.5 ± 1.14
Month 24-4.8 ± 1.15-3.4 ± 1.07
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.458 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 1.2 · 95% CI -2.0 to 4.3
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.419 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: -1.4 · 95% CI -4.9 to 2.1
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.692 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.6 · 95% CI -2.3 to 3.4
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.357 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 1.6 · 95% CI -1.8 to 5.0
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.420 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 1.4 · 95% CI -2.0 to 4.7
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.380 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 1.4 · 95% CI -1.8 to 4.5
SecondaryLikert Scale for Participant's Satisfaction With Care at Months 3, 6, 9, 12, 18 and 24

Participants measured their satisfaction with care by specifying their in response to the question "How satisfied are you with the results of your RA treatment?" on a 5-point Likert scale, from the following 5 answers: not satisfied, a little satisfied, moderately satisfied, well satisfied, very well satisfied. Scores range from 1 to 5, with higher scores indicating more satisfaction with their care.

Time frame:
Months 3, 6, 9, 12, 18, 24
Reported as:
Least squares mean · units on a scale
Likert Scale for Participant's Satisfaction With Care at Months 3, 6, 9, 12, 18 and 24
units on a scaleStandard of CareEarly Adalimumab
Month 33.5 ± 0.204.1 ± 0.19
Month 63.3 ± 0.194.1 ± 0.18
Month 93.7 ± 0.174.1 ± 0.17
Month 123.9 ± 0.164.2 ± 0.15
Month 184.2 ± 0.174.2 ± 0.16
Month 244.1 ± 0.164.3 ± 0.15
Statistical analysis
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.046 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.6 · 95% CI 0.0 to 1.1The a priori threshold for statistical significance is P=0.05.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.003 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.8 · 95% CI 0.3 to 1.3The a priori threshold for statistical significance is P=0.01.
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.204 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.3 · 95% CI -0.2 to 0.8
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.227 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.3 · 95% CI -0.2 to 0.7
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.860 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.0 · 95% CI -0.4 to 0.5
  • Standard of Care vs Early Adalimumab · ANCOVA · p = 0.476 (P-values are two-sided and are based on ANCOVA model with treatment group as the fixed effect and Baseline value as the covariate.) · Ls mean difference: 0.2 · 95% CI -0.3 to 0.6
SecondaryHealth Care Resources Questionnaire (HCR): Medical Insurance at Baseline

The HCR consists of four aspects: medical insurance, health care for RA in the past 4 weeks, hospitalization in the past 4 weeks, and out of pocket expenses incurred for the current study condition. Participants were asked whether and what type of health insurance they had. Types of Canadian insurance included: Régie de l'assurance maladie du Québec (RAMQ); Société de l'assurance automobile du Québec (SAAQ); Commission de la santé et de la sécurité du travail (CSST); Canadian Health Insurance Program (CHIP); and L'indemnisation des victimes d'actes criminals (IVAC).

Time frame:
Baseline
Reported as:
Number · percentage of participants
Health Care Resources Questionnaire (HCR): Medical Insurance at Baseline
percentage of participantsStandard of CareEarly Adalimumab
Has health insurance; n=35, 3971.471.8
1 insurance; n=35, 3971.466.7
>/= 1 insurance; n=35, 3902.6
RMAQ; n=25, 284.03.6
SAAQ; n=25, 2800
Federal government; n=25, 2803.6
CSST; n=25, 2800
OHIP; n=25, 2812.021.4
IVAC; n=25, 2800
Blue Cross; n=25, 2820.07.1
Other; n=25, 2864.064.3
SecondaryHCR: Medical Insurance at Final Visit

The HCR consists of four aspects: medical insurance, health care for RA in the past 4 weeks, hospitalization in the past 4 weeks, and out of pocket expenses incurred for the current study condition. Participants were asked whether and what type of health insurance they had. Types of Canadian insurance included: Régie de l'assurance maladie du Québec (RAMQ); Société de l'assurance automobile du Québec (SAAQ); Commission de la santé et de la sécurité du travail (CSST); Canadian Health Insurance Program (CHIP); and L'indemnisation des victimes d'actes criminals (IVAC).

Time frame:
Final Visit (up to Month 24)
Reported as:
Number · percentage of participants
HCR: Medical Insurance at Final Visit
percentage of participantsStandard of CareEarly Adalimumab
Has health insurance; n=33, 3778.870.3
1 insurance; n=33, 3778.870.3
>/= 1 insurance; n=33, 3700
RMAQ; n=26, 2603.8
SAAQ; n=26, 2600
Federal government; n=26, 2603.8
CSST; n=26, 2600
OHIP; n=26, 2611.511.5
IVAC; n=26, 2600
Blue Cross; n=26, 2611.57.7
Other; n=26, 2676.973.1
SecondaryHCR: Health Care for RA in the Past 4 Weeks at Baseline

The HCR consists of four aspects: medical insurance, health care for RA in the past 4 weeks, hospitalization in the past 4 weeks, and out of pocket expenses incurred for the current study condition. Participants were asked about their use of health care for RA in the past 4 weeks.

Time frame:
Baseline
Reported as:
Number · percentage of participants
HCR: Health Care for RA in the Past 4 Weeks at Baseline
percentage of participantsStandard of CareEarly Adalimumab
Used health care in past 4 weeks; n=35, 3934.125.6
Unscheduled visits to study doctor; n=11, 1027.320.0
Visits to another physician; n=11, 1027.30
Visits to a healthcare professional; n=11, 109.120.0
Visit to hospital emergency room; n=11, 10010.0
Use of an ambulance service; n=11, 1000
Complementary/alternative therapy visits; n=11, 1000
SecondaryHCR: Health Care for RA in the Past 4 Weeks at Final Visit

The HCR consists of four aspects: medical insurance, health care for RA in the past 4 weeks, hospitalization in the past 4 weeks, and out of pocket expenses incurred for the current study condition. Participants were asked about their use of health care for RA in the past 4 weeks.

Time frame:
Final Visit (up to Month 24)
Reported as:
Number · percentage of participants
HCR: Health Care for RA in the Past 4 Weeks at Final Visit
percentage of participantsStandard of CareEarly Adalimumab
Used health care in past 4 weeks; n=33, 376.18.1
Unscheduled visits to study doctor; n=2, 300
Visits to another physician; n=2, 3033.3
Visits to a healthcare professional; n=2, 350.033.3
Visit to hospital emergency room; n=2, 3033.3
Use of an ambulance service; n=2, 300
Complementary/alternative therapy visits; n=2, 300
SecondaryHCR: Out of Pocket Expenses Incurred for the Current Study Condition in the Past 4 Weeks at Baseline

The HCR consists of four aspects: medical insurance, health care for RA in the past 4 weeks, hospitalization in the past 4 weeks, and out of pocket expenses incurred for the current study condition. Participants were asked what type of out-of-pocket expenses they had incurred for their RA in the past 4 weeks. Based on Canadian dollars.

Time frame:
Baseline
Reported as:
Mean · Canadian dollars
HCR: Out of Pocket Expenses Incurred for the Current Study Condition in the Past 4 Weeks at Baseline
Canadian dollarsStandard of CareEarly Adalimumab
Over-the-counter medications; n=11, 1434.2 ± 28.160.3 ± 62.82
Health care professional payments; n=0, 2NA ± NA60.0 ± 28.28
Medical procedures/laboratory tests; n=0, 0NA ± NANA ± NA
Medical devices; n=2, 260.0 ± 56.5797.5 ± 31.82
Healthcare or extra help at home; n=0, 1NA ± NA80.0 ± NA
Transportation costs; n=17, 1236.3 ± 19.5330.3 ± 18.24
SecondaryHCR: Out of Pocket Expenses Incurred for the Current Study Condition in the Past 4 Weeks at Final Visit

The HCR consists of four aspects: medical insurance, health care for RA in the past 4 weeks, hospitalization in the past 4 weeks, and out of pocket expenses incurred for the current study condition. Participants were asked what type of out-of-pocket expenses they had incurred for their RA in the past 4 weeks. Based on Canadian dollars.

Time frame:
Final Visit (up to Month 24)
Reported as:
Mean · Canadian dollars
HCR: Out of Pocket Expenses Incurred for the Current Study Condition in the Past 4 Weeks at Final Visit
Canadian dollarsStandard of CareEarly Adalimumab
Over-the-counter medications; n=7, 7108.3 ± 78.7534.4 ± 32.82
Health care professional payments; n=1, 345.0 ± NA91.7 ± 43.68
Medical procedures/laboratory tests; n=0, 0NA ± NANA ± NA
Medical devices; n=0, 0NA ± NANA ± NA
Healthcare or extra help at home; n=0, 0NA ± NANA ± NA
Transportation costs; n=4, 461.3 ± 40.9035.0 ± 17.32

Adverse events

Collected over Baseline through Month 24 (± 10 days) plus 70 days follow-up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard of Care—3/35 (8.6%)32/35 (91.4%)
Early Adalimumab—4/39 (10.3%)33/39 (84.6%)
Most frequent serious events
Most frequent serious events
EventStandard of CareEarly Adalimumab
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/350/39
LUNG NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/350/39
PSYCHOTIC DISORDERPsychiatric disorders1/350/39
SURGICAL FAILUREGeneral disorders0/351/39
HERPES ZOSTERInfections and infestations0/351/39
ACUTE MYELOID LEUKAEMIANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/351/39
BREAST CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/351/39
Most frequent other events
Showing 10 of 58
Most frequent other events
EventStandard of CareEarly Adalimumab
RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders8/3510/39
NASOPHARYNGITISInfections and infestations7/358/39
NAUSEAGastrointestinal disorders6/351/39
HEADACHENervous system disorders6/352/39
DEPRESSIONPsychiatric disorders6/352/39
ALANINE AMINOTRANSFERASE INCREASEDInvestigations3/356/39
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations2/356/39
RASHSkin and subcutaneous tissue disorders5/354/39
INJECTION SITE REACTIONGeneral disorders2/355/39
BLOOD CHOLESTEROL INCREASEDInvestigations1/355/39

Baseline characteristics

Intent-to-treat population: all participants who were randomized and received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Standard of CareEarly AdalimumabTotal
Mean53.8 ± 10.4651.9 ± 11.5552.8 ± 11.01
Age, Customized
Age, Customized(participants)Standard of CareEarly AdalimumabTotal
< 65 years303464
>/= 65 years5510
Sex: Female, Male
Sex: Female, Male(Participants)Standard of CareEarly AdalimumabTotal
Female242650
Male111324
08

Study locations

No study locations are listed for this record.

09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2010
First posted
Jul 14, 2010
Start
Sep 2010
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results first posted
Nov 1, 2016
Last update
Nov 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01162421
Responsible party
Sponsor
First posted
Jul 14, 2010
Start date
Sep 2010
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Nov 1, 2016
Last update
Nov 1, 2016

Study contacts

Christina Pelizon, MD
study director · AbbVie Corporation
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adalimumab · Methotrexate

Start the discussion